At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 110 enrolled
Drug / intervention
GSK's candidate Mycobacterium tuberculosis vaccine 692342 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Reactogenicity & Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Administered Intramuscularly According to a Schedule of 0, 1 Month, to Healthy Adults Aged 18 to 50 Years
In Brief
A Phase 2 clinical trial evaluating GSK's candidate Mycobacterium tuberculosis vaccine 692342, Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system, and 2 other interventions for Tuberculosis. Completed, enrolled 110 participants across 1 site.
Detailed Summary
This study will assess the safety and immunogenicity of 2 different formulations of tuberculosis vaccine GSK692342 in healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTuberculosis
CountriesBelgium
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2006
Enrollment StartNov 2006
Primary CompletionDec 2009
TodayJul 2026
First PostedNov 10, 2006
Enrollment StartNov 15, 2006
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 19.6 years ago
Interventions
GSK's candidate Mycobacterium tuberculosis vaccine 692342biological
Intramuscular injection, 2 doses at 0, 1 month
Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant systembiological
Intramuscular injection, 2 doses at 0, 1 month
Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological salinebiological
Intramuscular injection, 2 doses at 0, 1 month
Control vaccine with the adjuvant system.biological
Intramuscular injection, 2 doses at 0, 1 month